

Resource Summary Report

Generated by [dkNET](#) on Aug 18, 2026

APC anti-mouse CD11c

RRID:AB_313779

Type: Antibody

Proper Citation

BioLegend Cat# 117310, RRID:AB_313779

Antibody Information

URL: http://antibodyregistry.org/AB_313779

Proper Citation: BioLegend Cat# 117310, RRID:AB_313779

Target Antigen: CD11c

Host Organism: armenian hamster

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-mouse CD11c

Description: This monoclonal targets CD11c

Target Organism: mouse

Clone ID: Clone N418

Antibody ID: AB_313779

Vendor: BioLegend

Catalog Number: 117310

Alternative Catalog Numbers: 117309

Record Creation Time: 20250819T215122+0000

Record Last Update: 20250820T001844+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-mouse CD11c.

No alerts have been found for APC anti-mouse CD11c.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 122 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Tang R, et al. (2026) Neoantigens and shared MICB ?3 antigen dual-targeted vaccine generates potent antitumor immunity. EMBO molecular medicine, 18(6), 2098.

Kureshi CTS, et al. (2026) Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. Cancer cell, 44(7), 1381.

Wang J, et al. (2026) VISTA neutralization by immunization reprograms immunosuppression and augments vaccine efficacy in renal carcinoma. Journal for immunotherapy of cancer, 14(5).

Sandoval TA, et al. (2026) Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer. Cancer research, 86(7), 1639.

Zhang SW, et al. (2026) Sensory neurons drive immune exclusion by stimulating a dense extracellular matrix in the breast cancer tumor microenvironment. Cell, 189(4), 1039.

Cheng G, et al. (2026) Ablation of the adhesion G protein-coupled receptor ADGRL1 activates anti-tumor immune response via cDC1-T cell hub formation. Cell reports, 45(6), 117409.

Tsuruta A, et al. (2026) The circadian clock component BMAL1 enhances macrophage inflammation by nuclear translocation of peroxisomal ?-oxidation enzyme MFP2. Cell reports, 45(6), 117480.

Stierli S, et al. (2026) A peripheral glial niche orchestrates the early stages of skin wound healing. Cell stem cell.

Han F, et al. (2026) VEGFR2 inhibition potentiates STING-mediated antitumor immunity. Cell reports, 45(7), 117576.

Arnett E, et al. (2026) Mycobacterium tuberculosis subverts macrophage-mediated defense through exploitation of the Zn transporter ZIP8. iScience, 29(6), 116276.

Zhang H, et al. (2026) Programmable iPSC-derived CAR-NK vesicles remodel the immune microenvironment and eradicate tumors. Cell reports. Medicine, 7(2), 102545.

Abdelfattah N, et al. (2026) Male-biased Yap1-Cd276/B7-H3 axis for immune evasion in medulloblastoma. *Cancer cell*, 44(4), 760.

Guo J, et al. (2026) VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment. *Cancer immunology research*, 14(5), 718.

Yang S, et al. (2026) Oat- β -glucan potentiates anti-PD-1 efficacy through *Faecalibacterium prausnitzii*-derived butyrate and indole-3-propionic acid. *Cell host & microbe*, 34(7), 1333.

Zhao J, et al. (2026) Reprogramming bacterial energetics reverses lactate-mediated immunosuppression for synergistic cancer immunotherapy. *Trends in biotechnology*.

Shao LJ, et al. (2026) Myeloid MMP14 couples extracellular proteolysis to inflammatory and metabolic remodeling during obesity. *Cell reports*, 45(7), 117681.

Taguchi S, et al. (2026) Induced pluripotent stem cell-derived dendritic cells potentiate the efficacy of interleukin-12-expressing oncolytic HSV-1. *Molecular therapy. Oncology*, 34(2), 201252.

Olea XD, et al. (2026) Tryptophan degradation by intestinal *Bacteroides* induces anti-tumor immunity and limits melanoma growth. *Cell reports. Medicine*, 7(7), 102921.

Ye K, et al. (2026) Direct interaction of V β 7 TCRs with IL17RA drives the differentiation of TH1-like $\gamma\delta$ T cells. *Science (New York, N.Y.)*, 393(6808), eadx9264.

Chen J, et al. (2025) Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients. *Cancer cell*, 43(3), 361.